Other contributors of acquired resistance to venetoclax in CLL have been identified using whole-exome sequencing of samples from CLL patients relapsing early during venetoclax therapy, including homozygous deletions of CDKN2A/B and BTG1 mutations [110]. Here, BTG1 is linked to B-cell chronic lymphocytic leukemia.